WO2026055603A1 - Peptides mimétiques d'apolipoprotéine a-i et procédés d'utilisation - Google Patents

Peptides mimétiques d'apolipoprotéine a-i et procédés d'utilisation

Info

Publication number
WO2026055603A1
WO2026055603A1 PCT/US2025/045357 US2025045357W WO2026055603A1 WO 2026055603 A1 WO2026055603 A1 WO 2026055603A1 US 2025045357 W US2025045357 W US 2025045357W WO 2026055603 A1 WO2026055603 A1 WO 2026055603A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
seq
amino
acid
aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/045357
Other languages
English (en)
Inventor
Gattadahalli M. Anantharamaiah
C. Roger White
Christine Angela CURCIO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Publication of WO2026055603A1 publication Critical patent/WO2026055603A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des peptides ou des fragments de ceux-ci pouvant se lier à des lipides oxydés, des hydroperoxydes lipidiques ou des lipopolysaccharides, et une composition pharmaceutique contenant les peptides ou les fragments et des procédés d'utilisation pour améliorer l'activité anti-oxydante du plasma PON-1, réduire le risque ou soulager les symptômes d'une maladie inflammatoire médiée par les lipides ou traiter un trouble lipidique.
PCT/US2025/045357 2024-09-09 2025-09-08 Peptides mimétiques d'apolipoprotéine a-i et procédés d'utilisation Pending WO2026055603A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463692330P 2024-09-09 2024-09-09
US63/692,330 2024-09-09

Publications (1)

Publication Number Publication Date
WO2026055603A1 true WO2026055603A1 (fr) 2026-03-12

Family

ID=99014883

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/045357 Pending WO2026055603A1 (fr) 2024-09-09 2025-09-08 Peptides mimétiques d'apolipoprotéine a-i et procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2026055603A1 (fr)

Similar Documents

Publication Publication Date Title
KR101022577B1 (ko) 항원성이 감소한 중합체 콘쥬게이트, 이의 제조방법 및용도
US8129330B2 (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EP3137103B1 (fr) Méthodes et compositions pour la modulation du système immunitaire à l'aide de l'arginase i
JPH08510255A (ja) 接合−安定化ポリペプチド組成物
JPH11511131A (ja) 共役結合を安定化させた治療薬組成物、投与および診断用配合物
JP2006321808A (ja) 化学的に修飾されたヒト成長ホルモンコンジュゲート
EA037083B1 (ru) Иммуномодулирующий конъюгат, включающий il-2 и водорастворимые полимеры
PL196533B1 (pl) Sposób stopniowego przyłączania ugrupowań poli (glikolu etylenowego) (PEG) szeregowo do polipeptydu
KR20070030308A (ko) 중합체­인자 ｉｘ 부분의 접합체
JP2011184442A (ja) Ｉｌ−２１の誘導体
TW200914617A (en) Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
JP2002522399A (ja) Ｐｅｇ−尿酸酸化酵素結合体およびその使用
JP2008509889A (ja) ペグ化インターフェロンα−１ｂ
HUP0300133A2 (en) Amphiphilic polymers and polypeptide conjugates comprising same
CN114761422B (zh) 白细胞介素-22的治疗性衍生物
WO2016145388A1 (fr) Conjugués d'une fraction d'il-7 et d'un polymère
JP2017205120A (ja) コリンエステラーゼ部分とポリマーとのコンジュゲート
AU2021203645B2 (en) Composition for prevention or treatment of hyperlipidemia comprising trigonal glucagon/GLP-1/GIP receptor agonist or conjugate thereof and method using the same
JP2007533298A (ja) Ｉｌ−２１の誘導体
WO2006102659A2 (fr) Conjugues d'un fragment de hgh et d'un polymere
US20240002467A1 (en) Compositions and methods of inhibiting the binding of plasma igg autoantibodies to serotonin 2a receptor
JP2026084695A (ja) グルカゴン、ｇｌｐ－１及びｇｉｐ三重活性体の持続型結合体の液状製剤
CN118891057A (zh) 肝脏靶向物质及其用途
EP2251033A1 (fr) Formulations pharmaceutiques comprenant de la paraoxonase
JP5058980B2 (ja) 粘膜炎を処置するための増殖因子ａｍｐ−１８に由来するペプチドの使用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25864418

Country of ref document: EP

Kind code of ref document: A1